Other studies [15, 16] have since correlated SLC45A3-ELK4 expression with an unfavorable prostate cancer prognosis, resulting in a growing interest in fusion transcription in the prostate cancer biomarker field [17, 18]. This evidence concerns the gene SLC45A3 and prostate carcinoma.